U.S. Food and Drug Administration App...

U.S. Food and Drug Administration Approves POMALYSTA (pomalidomide)...

Celgene Corporation today announced the U.S. Food and Drug Administration has approved POMALYST brand therapy for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Start the conversation, or Read more at Freshnews.

More from around the web